NewsBenzingaOppenheimer reitera su recomendación de “outperform” sobre Xeris Biopharma Holdings y eleva su precio objetivo a 21 dólares. Oppenheimer reitera su recomendación de “outperform” sobre Xeris Biopharma Holdings y eleva su precio objetivo a 21 dólares. Benzinga 2026.11.06 17:33 (GMT+0) Open on Benzinga Other news AI models can be tricked into identifying civilians as military targets by telling them it’s a game Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT